Nemus Bioscience is moving forward with Catalent Pharma Solutions to advance development of a human-dosage suppository formulation of NB1222, the prodrug of tetrahydrocannabinol (THC).
NB1222, also known as THC-valine-hemisuccinate (THC-val-HS), is being developed for the treatment and management of chemotherapy-induced nausea and vomiting. NB1222 is synthetically manufactured and is not plant-derived.
“A formulation that could provide reliable and predictable bioavailability and pharmacokinetics could leverage other valuable physiological attributes associated with cannabinoids,” said Brian Murphy, CEO and Chief Medical Officer of Nemus. “Such as appetite stimulation, along with anxiolytic and pain mitigation.”
A formulation with reliable bioavailability could leverage valuable attributes of cannabinoids.
“Catalent's softgel technology is a great delivery choice for NB1222,” said Aris Gennadios, President of Catalent Softgel Technologies.
“With the convenience that softgel can offer, combined with a lipid formulation to enhance bioavailability and help assure dose uniformity, we expect Nemus to be well positioned to pursue development of an efficacious drug product.”
“The global CINV market is a multi-billion dollar opportunity with projected growth as populations live longer, increasing the likelihood of developing a malignancy over time,” added Murphy.
“THC-val-HS now has a patent footprint in major markets worldwide and we look forward to also advancing this prodrug into formulation activity for the glaucoma indication, using our candidate molecule NB1111.”
